Related Experiment Video
Updated: May 13, 2026

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
Published on: June 18, 2018
Establishing the feasibility of measuring performance in use of addiction pharmacotherapy
Cindy Parks Thomas1, Deborah W Garnick, Constance M Horgan
1Schneider Institutes for Health Policy, Brandeis University, Waltham, MA 02454, USA. cthomas@brandeis.edu
Abstract:
This paper presents the rationale and feasibility of standardized performance measures for use of pharmacotherapy in the treatment of substance use disorders (SUD), an evidence-based practice and critical component of treatment that is often underused. These measures have been developed and specified by the Washington Circle, to measure treatment of alcohol and opioid dependence with FDA-approved prescription medications for use in office-based general health and addiction specialty care. Measures were pilot tested in private health plans, the Veterans Health Administration (VHA), and Medicaid. Testing revealed that use of standardized measures using administrative data for overall use and initiation of SUD pharmacotherapy is feasible and practical. Prevalence of diagnoses and use of pharmacotherapy vary widely across health systems. Pharmacotherapy is generally used in a limited portion of those for whom it might be indicated. An important methodological point is that results are sensitive to specifications, so that standardization is critical to measuring performance across systems.
Related Concept Videos
Drug Abuse and Addiction: Pharmacological Phenomena
Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Therapeutic Drug Monitoring: Affecting Factors
Measurement of Bioavailability: Pharmacokinetic Methods
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...

